CSL Limited CSLLY Stock
CSL Limited Price Chart
CSL Limited CSLLY Financial and Trading Overview
| CSL Limited stock price | 32 USD |
| Previous Close | 31.44 USD |
| Open | 31 USD |
| Bid | 31.08 USD x 60000 |
| Ask | 31.12 USD x 10000 |
| Day's Range | 30.95 - 31.24 USD |
| 52 Week Range | 16.01 - 36.29 USD |
| Volume | 4.45K USD |
| Avg. Volume | 201.39K USD |
| Market Cap | 59.83B USD |
| Beta (5Y Monthly) | 0.125 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.34 USD |
| Forward Dividend & Yield | 0.72 (2.31%) |
| Ex-Dividend Date | September 10, 2026 |
| 1y Target Est | 32 USD |
CSLLY Valuation Measures
| Enterprise Value | 70.6B USD |
| Trailing P/E | N/A |
| Forward P/E | 17.89826 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.7875528 |
| Price/Book (mrq) | 4.035343 |
| Enterprise Value/Revenue | 4.469 |
| Enterprise Value/EBITDA | 13.904 |
Trading Information
CSL Limited Stock Price History
| Beta (5Y Monthly) | 0.125 |
| 52-Week Change | -4.16% |
| S&P500 52-Week Change | 15.65% |
| 52 Week High | 36.29 USD |
| 52 Week Low | 16.01 USD |
| 50-Day Moving Average | 26.98 USD |
| 200-Day Moving Average | 25.13 USD |
CSLLY Share Statistics
| Avg. Volume (3 month) | 201.39K USD |
| Avg. Daily Volume (10-Days) | 97.38K USD |
| Shares Outstanding | 1.92B |
| Float | 1.91B |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.0069% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 2.92 |
| Trailing Annual Dividend Yield | 9.28% |
| 5 Year Average Dividend Yield | 151.00% |
| Payout Ratio | 0.4457 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | -16.32% |
| Operating Margin (ttm) | 21.48% |
| Gross Margin | 51.11% |
| EBITDA Margin | 32.14% |
Management Effectiveness
| Return on Assets (ttm) | 7.25% |
| Return on Equity (ttm) | -15.83% |
Income Statement
| Revenue (ttm) | 15.8B USD |
| Revenue Per Share (ttm) | 8.19 USD |
| Quarterly Revenue Growth (yoy) | 5.50% |
| Gross Profit (ttm) | 8.07B USD |
| EBITDA | 5.08B USD |
| Net Income Avi to Common (ttm) | -2579000064 USD |
| Diluted EPS (ttm) | -1.34 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.51B USD |
| Total Cash Per Share (mrq) | 0.79 USD |
| Total Debt (mrq) | 10.9B USD |
| Total Debt/Equity (mrq) | 66.82 USD |
| Current Ratio (mrq) | 2.21 |
| Book Value Per Share (mrq) | 7.72425 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 3.51B USD |
| Levered Free Cash Flow (ttm) | 1.89B USD |
Profile of CSL Limited
| Country | United States |
| State | VIC |
| City | Melbourne |
| Address | 655 Elizabeth Street |
| ZIP | 3000 |
| Phone | 61 3 9389 1911 |
| Website | https://www.csl.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 29000 |
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Q&A For CSL Limited Stock
What is a current CSLLY stock price?
CSL Limited CSLLY stock price today per share is 32 USD.
How to purchase CSL Limited stock?
You can buy CSLLY shares on the OTC Markets OTCQX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CSL Limited?
The stock symbol or ticker of CSL Limited is CSLLY.
Which industry does the CSL Limited company belong to?
The CSL Limited industry is Biotechnology.
How many shares does CSL Limited have in circulation?
The max supply of CSL Limited shares is 1.92B.
What is CSL Limited Price to Earnings Ratio (PE Ratio)?
CSL Limited PE Ratio is now.
What was CSL Limited earnings per share over the trailing 12 months (TTM)?
CSL Limited EPS is -1.34 USD over the trailing 12 months.
Which sector does the CSL Limited company belong to?
The CSL Limited sector is Healthcare.
